Wall Street Pummels Seres Therapeutics Inc. (MCRB) After Recent Earnings Report

Seres Therapeutics Inc. (NASDAQ:MCRB) went down by -0.54% from its latest closing price compared to the recent 1-year high of $9.49. The company’s stock price has collected 1.48% of gains in the last five trading sessions.

Is It Worth Investing in Seres Therapeutics Inc. (NASDAQ :MCRB) Right Now?

Plus, the 36-month beta value for MCRB is at 2.76.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could “deliver huge returns.” Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our
5 Best Growth Stocks To Own For 2023.


MCRB currently public float of 116.29M and currently shorts hold a 5.85% ratio of that float. Today, the average trading volume of MCRB was 814.42K shares.

MCRB’s Market Performance

MCRB stocks went up by 1.48% for the week, with a monthly drop of -17.84% and a quarterly performance of -22.82%, while its annual performance rate touched -32.01%. The volatility ratio for the week stands at 6.18% while the volatility levels for the past 30 days are set at 6.49% for Seres Therapeutics Inc. The simple moving average for the period of the last 20 days is 0.17% for MCRB stocks with a simple moving average of 1.31% for the last 200 days.

Analysts’ Opinion of MCRB

Many brokerage firms have already submitted their reports for MCRB stocks, with Goldman repeating the rating for MCRB by listing it as a “Sell.” The predicted price for MCRB in the upcoming period, according to Goldman is $7 based on the research report published on July 23rd of the previous year 2021.

Goldman, on the other hand, stated in their research note that they expect to see MCRB reach a price target of $24. The rating they have provided for MCRB stocks is “Neutral” according to the report published on May 18th, 2021.

Chardan Capital Markets gave a rating of “Buy” to MCRB, setting the target price at $30 in the report published on March 05th of the previous year.

MCRB Trading at -14.96% from the 50-Day Moving Average

After a stumble in the market that brought MCRB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -42.26% of loss for the given period.

Volatility was left at 6.49%, however, over the last 30 days, the volatility rate increased by 6.18%, as shares sank -11.47% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -39.45% lower at present.

During the last 5 trading sessions, MCRB rose by +1.48%, which changed the moving average for the period of 200-days by -26.64% in comparison to the 20-day moving average, which settled at $5.43. In addition, Seres Therapeutics Inc. saw -2.14% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at MCRB starting from Ege David S., who sale 5,012 shares at the price of $7.93 back on Oct 31. After this action, Ege David S. now owns 46,734 shares of Seres Therapeutics Inc., valued at $39,745 using the latest closing price.

Nutritional Health LTP Fund Ge, the 10% Owner of Seres Therapeutics Inc., purchase 8,738,243 shares at $3.15 during a trade that took place back on Jul 05, which means that Nutritional Health LTP Fund Ge is holding 5,875,711 shares at $27,525,465 based on the most recent closing price.

Stock Fundamentals for MCRB

Equity return is now at value -305.30, with -73.50 for asset returns.